This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Launching orphan medicines excellently will become even more important over the next five years as more patients with rare diseases have pharmacotherapies available. There are also a growing number of disease-focussed registries, increasing public and policy maker awareness, and significant R&D investment in orphan drugs, as well as in digital technologies to support trials and treatment.
Although approach differs slightly amongst organizations in clinical research, everyone agrees on this: it’s time for the industry to become more agile. Too many life-saving treatments and medical advancements are at stake to remain attached to the traditional ways of data collection. Over the past ten years, we’ve seen things slowly going the way of virtual clinical trials.
With two busy 2019 quarters booked, Pharma Packaging Solutions knew it needed to expand capacity quickly. Investments totaling over $2,7 million were made in several areas. One major investment included additional portable serialization and aggregation equipment to improve efficiency on primary and secondary lines. Additional labeling equipment was ordered and installed along with a leading-edge environmental control system.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content